Accelerating and de-risking the discovery of breakthrough medicines for complex neurological disorders.
Dive into our
Patient-derived brain organoids are a powerful platform for CNS drug discovery.
Living, self-organized 3D structures derived from human iPSCs that mimic human brain tissue and exhibit highly synchronized and spontaneous synaptic network activity.
Biomarker-based Screening Endpoints
Capture robust and reproducible clinically translatable disease phenotypes that are amenable to multiple screening applications and high-content imaging.
De-risking Clinical Translation
Accelerate the generation of human efficacy and safety data, early in the R&D process, resulting in safer and more effective clinical candidates, enhancing clinical translation.
FDA Modernization Act 2
Recognizes that human brain organoids provide a more accurate and reliable evaluation of drug efficacy and safety reducing the reliance on animal work.